Author(s) :

Sabeeka Sajjal, Rabia Ahmed, Aishmal.

Volume/Issue :

Abstract :

One of the main causes of lower respiratory tract disorders in both young infants and the elderly is respiratory syncytial virus (RSV). Despite being discovered in 1955, there is still no effective RSV vaccine, and the only approved treatment is the use of a humanized monoclonal antibody for passive immunoprophylaxis in high-risk newborns. Furthermore, recurrent wheeze and asthma in infancy and children are linked to early-life RSV infection. There are four main ways that respiratory syncytial viruses can spread: by direct physical touch, indirect contact (fomite), big droplets, and small aerosols. To determine the efficacy of non-pharmaceutical interventions in the population, it is essential to comprehend the relative contributions of various mechanisms of transmission. It ought to be more efficient to interfere with several transmission modalities rather than just one. In RSV season, palivizumab is being administered. Numerous vaccines and drugs have been developed as a result of recent advancements.

No. of Downloads :

3